44 results about "Serum concentration" patented technology

The invention relates to the technical field of tumor risk assessment, and discloses a multi-modal deep learning-based ovarian adnexal tumor risk grading system, which comprises a multi-modal data acquisition module for acquiring ultrasonic image data, CA125 serum concentration data and gold standard data of an ovarian adnexal tumor patient; the ultrasonic image segmentation module is used for carrying out automatic positioning and structured segmentation on a focus area of the ultrasonic image by adopting self-adaptive bidirectional displacement; the multi-modal feature extraction module is used for extracting an O-RADS vector and a CEUS vector according to the focus area mask of the segmented image, and carrying out numerical value normalization processing on the CA125 serum concentration data to obtain a standardized feature vector; the multi-modal feature fusion module carries out feature fusion to obtain OCC-US vector representation; and the risk grading decision module is used for classifying the OCC-US vector representation and outputting an OCC-US score and a benign and malignant risk grade. According to the invention, the diagnosis precision and reliability of the ovarian adnexal tumor are improved.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

The invention relates to the technical field of biological detection, and particularly discloses a method for simultaneously determining serum concentrations of an anti-epileptic drug and active metabolites thereof based on an LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry) method. According to the method, the C18 chromatographic column with the filler particle size of 3.0 microns is selected for the first time, efficient separation of lamotrigine, levetiracetam, oxcarbazepine and active metabolites thereof is achieved, and the separation efficiency is equivalent to that of a small-particle-size column; a pretreatment process is simplified by precipitating protein through a single organic solvent, and accurate quantification of four components is completed by only using two isotope internal standard oxcarbazep-d4 and levetiracetam-d6, so that the cost is reduced. In the aspect of the detection range, the lower quantification limit of oxcarbazepine is broken through to 0.04 [mu] g.mL <-1 >, and the technical contradiction between oxcarbazepine and the upper quantification limit (as high as 50 [mu] g.mL <-1 >) of LEV across three orders of magnitude is overcome. According to the scheme, hardware requirements and reagent cost are reduced, and meanwhile, high sensitivity and a wide linear range are achieved.

The invention belongs to the technical field of microorganisms and compound nutrients, and particularly relates to a postbiotic preparation and composition for improving activity of gamma-aminobutyric acid and promoting calcium absorption and application of the postbiotic preparation and composition in sleep improvement and bone health. Through the synergistic effect of the specific metagen preparation and the gamma-aminobutyric acid, the multi-dimensional technical breakthrough is realized, and the physiological activity and the application value are remarkably improved. In the aspect of bioavailability, the intestinal barrier function is improved and the pH value of the intestinal tract is adjusted to be weakly acidic through the postbiotics, so that the concentration of serum GABA is increased by 2-3 times compared with that of single use, and the calcium absorption rate is increased from 30% to 55-60%. And on the aspect of function synergy, the limitation of single effect in the prior art is broken through, dual-function synergy of'sleep regulation-bone health 'is realized, meanwhile, the vicious circle of'poor sleep-calcium loss' is improved, and good practical application value is achieved.

To provide a therapeutic agent enabling treatment of a malignant tumor.SOLUTION: A therapeutic agent comprising a substance that recognizes a target expressed in an erythroblast, where the therapeutic agent is administered such that, during a dosing period, a serum concentration of the substance in a subject administered with the therapeutic agent is maintained at 10% or more of a maximum value after administration.SELECTED DRAWING: None

The disclosure provides improved human FGF23-binding antibodies with increased affinity for human FGF23 as compared to burosumab, enabling reduced dosing frequency, improving convenience of therapy, and achieving higher efficacy compared to burosumab, without compromising safety.

The invention belongs to the technical field of biological medicine, and relates to a novel application of endogenous substances in alcohol related liver disease (ALD). The invention proposes for the first time that an endogenous substance with regular concentration change in the ALD process can be used as a biomarker for auxiliary diagnosis and / or stage evaluation of ALD, the exogenous supplement of the endogenous substance has a prevention and treatment effect on ALD, and the endogenous substance has double values of being used as an excellent biomarker and an effective therapeutic agent. The substances include but are not limited to taurochenodeoxycholic acid (TCDCA), dehydroepiandrosterone sulfate (DHEA-S) and the like. Wherein the serum concentration of TCDCA is obviously increased along with disease progression, and the concentration of DHEA-S is obviously reduced. The diagnostic value of the substance on ALD is remarkably superior to that of a traditional liver injury marker, and ethanol-induced liver cell injury and mouse liver pathological change can be remarkably improved through exogenous supplementation. The invention provides a brand new strategy for accurate diagnosis and prevention of ALD.

The invention discloses a method for evaluating gastric cancer prognosis by using peripheral blood inflammation related markers, and belongs to the technical field of smart medical treatment. The method comprises the following steps: firstly, constructing an immune state model based on a ratio of neutrophil to lymphocyte and a ratio of platelet to lymphocyte, and outputting an immune state coefficient; constructing a nutrition state model based on serum albumin, globulin concentration and ratio of albumin to globulin, and outputting a nutrition state coefficient; then combining the coefficients with the serum IL-35 and IL-37 concentrations to construct an inflammation risk model, and outputting an inflammation risk coefficient; meanwhile, a behavioral environment state model is constructed based on the daily salt intake and the smoking age limit of the patient, and a behavioral environment state coefficient is output; and finally, integrating the inflammation risk coefficient, the behavior environment state coefficient and the prognosis nutrition index, and obtaining a prognosis evaluation coefficient through a prognosis state evaluation model. Through multi-dimensional and non-invasive index integration and modeling analysis, accurate, economic and convenient evaluation of gastric cancer prognosis is realized.

The present application relates to the method and the used heat lung clear granules of treating pneumonia, one aspect, it is related to the method such as investigating the effect of heat lung clear granules in treating pneumonia by determining serum TNF-alpha concentration, including the steps: mice are randomly divided, atomized modeling is used LPS, after modeling, heat lung clear granules are given by gavage, blood is taken from mice, serum is collected, at least one of the following items is determined: lung index, TNF-alpha, IL-1beta, LI-6, PGE2 content in serum, and the statistical result of the treatment effect of heat lung clear granules on mice with pneumonia is obtained according to the detection data.The present application also provides the use of heat lung clear granules as a pneumonia treatment drug.The present application shows that heat lung clear granules are a very good pneumonia treatment drug.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CST6 as a lung cancer brain metastasis early diagnosis marker. The core of the invention is to confirm that CST6 is used as a marker for early diagnosis and prediction of brain metastasis of lung cancer for the first time. In experimental verification, the CST6 protein expression quantity of the lung cancer cell strain H1975-BrM with high brain metastasis potential is remarkably higher than that of a common cell strain, an animal model further shows that overexpression of CST6 can promote formation of brain metastasis, and knock-down expression can inhibit metastasis capacity; clinical sample analysis shows that the serum CST6 concentration of brain metastasis patients is far higher than that of non-metastasis patients and healthy people, and the diagnostic value of CST6 is supported. In the aspect of diagnosis efficiency, the area under the ROC curve of the serum CST6 reaches 0.848, and high accuracy is shown. On the whole, the clinical blank is filled, and a reliable tool is provided for non-invasive lung cancer brain metastasis risk management.

The present invention relates to the technical field of Brucella detection. The present invention provides a Brucella-specific antigen and its application. The nucleotide sequence of the Brucella-specific antigen is shown in SEQ ID NO.1. The Brucella-specific antigen of the present invention has strong specificity and good use effect. A test strip prepared using the antigen of the present invention can still detect a significant positive reaction when the positive serum concentration is diluted to 1:40; the test strip of the present invention detects Yersinia intestinalis-positive serum and Escherichia coli-positive serum, and the results are both negative, indicating that the test strip has good specificity.

The present disclosure describes a method for preventing or treating an abnormal mammary gland cytopathy characterized by cell proliferation in a subject. The method comprises administering to the subject an effective amount of an androgen agent in combination with an effective amount of an aromatase inhibitor, increasing the concentration of the androgen agent in serum to a level to increase the intramammary concentration of androgen in the mammary gland resulting from the action of 5 alpha-reductase on the androgen agent, the increased intramammary concentration of the androgen induces inhibition of c-Myc and / or mTOR expression or activity in the mammary gland associated with a lower intramammary concentration of the androgen. The increase in the serum concentration of the androgen agent and the increase in the intramammary concentration of the androgen are maintained for a predetermined period of time without substantially increasing the concentration of the androgen in the serum of the subject. Furthermore, the use of the aforementioned androgen and aromatase inhibitors for reducing the risk of breast cancer progression to hormone-resistant breast cancer, reducing the risk of HER2-positive breast cancer becoming insensitive to targeted HER-2 anti-cancer drug therapy, and for inducing inhibition of c-Myc and / or mTOR expression and / or activity is also described. In embodiments, the androgen agent may be testosterone and androgen 5 [alpha]-dihydrotestosterone (DHT).

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

The present application relates to a compound for reducing the serum concentration of RBP4, a stereoisomer thereof, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or an acceptable salt of the deuterated derivative thereof, as well as a method for preparing the compound, a composition thereof, and a use therefor.

The invention discloses a health risk assessment method for association of PFAS concentration and cardiovascular-kidney-metabolic syndrome, and the method comprises the following specific implementation processes: obtaining concentration data of PFAS in serum of a crowd and related data of blood physicochemical and physicochemical measurement, and calculating the ten-year cardiovascular disease risk and renal function condition of a human body. The heart and kidney metabolic syndrome condition of an individual is staging to judge the health condition, and a threshold value of health risk improvement is established according to the serum PFAS concentration and related data of all samples in combination with the health condition. According to the method, accurate quantitative evaluation of multi-dimensional health risks is realized, the comprehensive influence of PFAS on human health is more comprehensively reflected through the heart and kidney metabolic syndrome, the health risk threshold of serum PFAS exposure is provided, and early warning is provided for high-risk people.

The invention is applicable to the technical field of biomedicine, and provides a serum protein marker, a kit and a detection method for early screening and diagnosis of pan cancer, the serum protein marker is RNASE4 protein, and the amino acid sequence of the serum protein marker is as shown in SEQ ID NO.1. The application finds that the serum concentration of the RNASE4 protein is remarkably related to various cancers for the first time, the RNASE4 protein can be used as an ideal marker for diagnosis of the pan-cancer, and the RNASE4 protein is provided as the pan-cancer marker, the matched kit and the detection method, so that the problems that the existing CA type marker is low in accuracy and sensitivity and easy to interfere are solved; high-specificity and high-sensitivity non-invasive early screening of intestinal cancer, pancreatic cancer, bladder cancer, breast cancer and ovarian cancer is achieved, the area under an ROC curve is larger than or equal to 0.85, detection operation is easy and convenient, and stability is good.

Methods are described for treating a localized infection of living tissue in a human patient in need thereof, which may include locally administering a daily dose of at least one antibiotic that substantially exceeds the maximum recommended daily dose of the at least one antibiotic, and providing a peak or trough serum concentration of the at least one antibiotic that is below the maximum safe serum concentration level.

The present application relates to a compound for reducing serum concentration of RBP4, a stereoisomer, a deuterated derivative, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of a stereoisomer or an acceptable salt of a deuterated derivative, and a method for preparing the compound, a composition and use thereof.

The present invention relates to a serological marker for the preoperative clinical diagnosis of ocular adnexal extranodal marginal zone lymphoma (OA-EMZL), belonging to the field of biomedicine. The present invention provides the use of a reagent for detecting serum IgM concentration in the preparation of a diagnostic kit for ocular adnexal extranodal marginal zone lymphoma; the use of a reagent for detecting serum IgM concentration in the preparation of a diagnostic kit for the differential diagnosis of ocular adnexal extranodal marginal zone lymphoma; and a diagnostic kit for ocular adnexal extranodal marginal zone lymphoma. The use of the present invention can reduce the cost of preoperative clinical diagnosis of OA-EMZL and address the difficulties in differential diagnosis.

To provide means and methods for extending the therapeutic window of pharmaceuticals that are locally delivered to the brain, preventing both export from the brain and systemic accumulation, thereby increasing the brain-to-serum ratio.SOLUTION: The present invention relates to a polypeptide comprising a crystallizable fragment (Fc) region of IgG for use in prevention or treatment of a disease, in particular a disease affecting a central nervous system. The polypeptide is administered locally to an affected compartment, in particular to the central nervous system. The Fc region bears a modification that results in reduced affinity to a neonatal Fc receptor (FcRn), thereby resulting in an increased brain-to-serum concentration of the polypeptide.SELECTED DRAWING: Figure 6A

This invention provides a method and system for predicting the potential of bovine in vitro embryo production based on AMH concentration, relating to the field of livestock reproductive technology. The method includes: obtaining a blood sample from a donor cow before the start of the in vitro embryo production cycle; performing serum separation processing on the blood sample to obtain a serum sample; detecting the anti-Müllerian hormone concentration in the serum sample to obtain a serum AMH concentration value; and predicting the number of follicles in the donor cow based on the serum AMH concentration value using a cubic polynomial regression model. This invention establishes serum AMH concentration as an objective biomarker for predicting bovine in vitro embryo production potential and constructs a corresponding quantitative prediction model, achieving early, non-invasive, and quantitative prediction of the individual potential of donor cows before incurring high production costs.

According to the application of the lucid ganoderma extract tablet in resisting depression, provided by the invention, the lucid ganoderma extract tablet can be used for remarkably increasing the preference degree of rats on sweet water, remarkably increasing the activity distance and standing times of the rats, remarkably reducing the immobility time of the rats, remarkably reducing the concentration of serum CORT of the rats and remarkably increasing the concentration of hippocampus and prefrontal cortex 5-HT of the rats; the concentration of rat hippocampus and prefrontal cortex NE is obviously increased, and the concentration of rat hippocampus and prefrontal cortex DA is obviously increased, so that the anti-depression effect is achieved.

Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.

To provide a formulation having a novel sustained release multi-phasic concentration pattern, particularly a formulation that can be used to reduce mammographic breast density and / or breast stiffness in warm-blooded animals.SOLUTION: For example, the formulation may include administration of an effective amount of an androgenic agent and an effective amount of an aromatase inhibitor to a subject, and provides a sustained release multiphasic concentration pattern in the blood of the subject over time, as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor, and particularly improves breast tissue stability and / or increases androgen receptor expression levels.SELECTED DRAWING: Figure 2

The present invention relates to the technical field of tumor risk assessment and discloses an ovarian adnexal tumor risk grading system based on multimodal deep learning. The system comprises: a multimodal data acquisition module for acquiring ultrasound imaging data, CA125 serum concentration data, and gold standard data of patients with ovarian adnexal tumors; an ultrasound image segmentation module for automatically locating and structurally segmenting ultrasound image lesion areas using adaptive bidirectional displacement; a multimodal feature extraction module for extracting O-RADS vectors and CEUS vectors based on lesion area masks from segmented images, and for performing numerical normalization processing on CA125 serum concentration data to obtain standardized feature vectors; a multimodal feature fusion module for performing feature fusion to obtain OCC-US vector representations; and a risk grading decision module for classifying the OCC-US vector representations and outputting OCC-US scores and benign and malignant risk levels. The present invention improves the diagnostic accuracy and reliability of ovarian adnexal tumors.

The invention discloses application of FSH as a biomarker for diagnosing autoimmune hepatitis, belongs to the technical field of gene diagnosis and treatment of molecular biology, and aims to solve the problem that recognition of a specific marker and biochemical characteristics of the autoimmune hepatitis still has certain challenging. It is found for the first time that the FSH (follicle stimulating hormone) content in serum of a patient with autoimmune hepatitis is significantly higher than that of a group of the same age group, and when the serum concentration exceeds 58.81 pg / ml, the Youden index reaches 100%, which indicates that the threshold value can ensure 100% diagnosis accuracy. Therefore, the CUTOFF value for diagnosing AIH (autoimmune hepatitis) is 58.81 pg / ml, and the accuracy reaches 100%; the research shows that the FSH content in the serum of the AIH patient has a potential value for diagnosing the AIH. Meanwhile, the FSH can also be used as a target spot for researching the autoimmune hepatitis treatment medicine.

The utility model relates to a portable blood taking card for rapidly detecting the serum concentration of vitamin K2, which comprises a card shell and a blood storage strip, and is technically characterized in that the card shell is rectangular and is provided with an opening in the side, an upper support cavity corresponding to the blood storage strip and a cooling object accommodating cavity positioned at the lower part of the upper support cavity are arranged in the card shell, a support shoulder is arranged between the upper support cavity and the cooling object accommodating cavity, and the support shoulder is provided with a clamping groove. The blood storage strip is provided with a blood storage cavity, a blood injection assembly communicated with the blood storage cavity is arranged on the upper surface of the blood storage strip, the edge of the lower surface of the blood storage strip is supported on the upper surface of the supporting shoulder, a large through hole is formed in the middle of the lower surface of the blood storage strip, and an anti-seepage protection film for blocking the large through hole is attached to the inner bottom face of the blood storage strip. Cooling gel used for being bonded with the blood storage strip and the lower surface of the anti-seepage protection film is sealed in the packaging bag in a sealed mode. Compared with an existing blood taking card, the vitamin K2 blood taking card ensures the preservation requirement before the concentration of vitamin K2 is detected, improves the detection accuracy, is convenient to carry and is suitable for independent and rapid inspection.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

Herein is reported a method for determining anti-AAV particle antibodies in a mammalian sample, the method comprising the steps of: diluting an aliquot of the sample, preferably to a final serum concentration of between 5% (v / v) and 0.5% (v / v); adding an AAV particle (AAVp) specifically bound by the anti-AAV particle antibody (AAV-ADA) to the diluted sample to produce a labeled sample; pre-incubating the labeled sample to allow the formation of an AAV-ADA-AAVp complex; and detecting the AAV-ADA-AAVp complex, thereby determining the anti-AAV antibody in the mammalian sample.

The invention relates to the technical field of biomarkers, in particular to application of a blood coagulation factor X as a biomarker influencing the abdominal fat percentage of chicken. The invention discloses a biomarker influencing the abdominal fat percentage of chicken. The biomarker is a blood coagulation factor X. Experimental data provided by the invention show that F10 shows a significant difference (Plt; P1t) between groups with high abdominal fat percentage (AFP > = 18%) and groups with low abdominal fat percentage (AFP < = 12%); 0.05), and the biochemical marker combination can be used as a specific molecular marker for the abdominal fat mass of the Gushi chicken. On the basis, a molecular marker assisted breeding system containing serum F10 concentration detection, TG level evaluation and phenotype data association analysis is established, and an innovative technical path is provided for high-quality breeding of Henan local chicken germplasm resources.